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Abstract
HIV persists in a small pool of latently infected cells despite antiretroviral therapy (ART).
Identifying cellular markers expressed at the surface of these cells may lead to novel thera-
peutic strategies to reduce the size of the HIV reservoir. We hypothesized that CD4+ T cells
expressing immune checkpoint molecules would be enriched in HIV-infected cells in individ-
uals receiving suppressive ART. Expression levels of 7 immune checkpoint molecules (PD-
1, CTLA-4, LAG-3, TIGIT, TIM-3, CD160 and 2B4) as well as 4 markers of HIV persistence
(integrated and total HIV DNA, 2-LTR circles and cell-associated unspliced HIV RNA) were
measured in PBMCs from 48 virally suppressed individuals. Using negative binomial
regression models, we identified PD-1, TIGIT and LAG-3 as immune checkpoint molecules
positively associated with the frequency of CD4+ T cells harboring integrated HIV DNA. The
frequency of CD4+ T cells co-expressing PD-1, TIGIT and LAG-3 independently predicted
the frequency of cells harboring integrated HIV DNA. Quantification of HIV genomes in
highly purified cell subsets from blood further revealed that expressions of PD-1, TIGIT and
LAG-3 were associated with HIV-infected cells in distinct memory CD4+ T cell subsets.
CD4+ T cells co-expressing the three markers were highly enriched for integrated viral
genomes (median of 8.2 fold compared to total CD4+ T cells). Importantly, most cells carry-
ing inducible HIV genomes expressed at least one of these markers (median contribution of
cells expressing LAG-3, PD-1 or TIGIT to the inducible reservoir = 76%). Our data provide
evidence that CD4+ T cells expressing PD-1, TIGIT and LAG-3 alone or in combination are
enriched for persistent HIV during ART and suggest that immune checkpoint blockers
directed against these receptors may represent valuable tools to target latently infected
cells in virally suppressed individuals.
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Author Summary
The persistence of HIV in a small pool of long-lived latently infected resting CD4+ T cells
is a major barrier to viral eradication. Identifying cellular markers that are preferentially
expressed at the surface of latently infected cells may lead to novel therapeutic strategies to
cure HIV infection. We identified PD-1, TIGIT and LAG-3 as markers preferentially
expressed at the surface of infected cells in individuals receiving ART. CD4+ T cells co-
expressing these markers were highly enriched for cells carrying HIV. Our results suggest
that PD-1, TIGIT and LAG-3 may represent new molecular targets to interfere with HIV
persistence during ART.
Introduction
Although antiretroviral therapy (ART) is highly effective at suppressing HIV replication, viral
reservoirs persist despite treatment and lead to rapid viral rebound when ART is interrupted
[1–4]. A major step to achieve natural control of HIV replication after ART cessation would be
to eliminate, or at least reduce, the number of long-lived infected cells from which HIV reignite
infection. The characterization of cell surface markers that could identify HIV-infected cells
persisting during ART is a research priority towards an HIV cure [5] as it could lead to the
development of novel eradication strategies.
Several subsets of CD4+ T cells harbor replication-competent HIV during ART. These
CD4+ T cells are usually defined on the basis of their differentiation stage [6–8], functionality
or homing potential [9,10]. Central memory (TCM) and transitional memory (TTM) CD4
+ T
cells were identified as the major cellular reservoirs for HIV during ART [6]. More recently, a
less differentiated subset of long-lived cells with high self-renewal capacity, the stem-cell mem-
ory CD4+ T cells (TSCM), has been identified as a main contributor to long-term HIV persis-
tence [7,8]. The functional and homing capacities of CD4+ T cells also dictate their capacity to
serve as persistent reservoirs for HIV: Th17 and Th1/Th17 CD4+ T cells as well as cells express-
ing CCR6 and CXCR3 show increasing contribution to the viral reservoir with duration of
ART [11,12].
Immune checkpoint molecules (ICs) are co-inhibitory receptors which down-modulate
immune responses to prevent hyper-immune activation, minimize collateral damage, and
maintain peripheral self-tolerance [13]. ICs are up regulated upon T-cell activation and con-
strain the effector response through feedback inhibition. Overexpression of these molecules is
associated with T-cell exhaustion and dysfunction in cancer and chronic viral infections,
including HIV [14–17]. We hypothesized that ICs, through their ability to inhibit T-cell activa-
tion, will favour HIV latency during ART, and that CD4+ T cells expressing ICs would be
enriched for persistent HIV in individuals receiving ART.
We focused our analysis on 7 ICs, namely PD-1 (programmed cell death-1), CTLA-4 (cyto-
toxic T-lymphocyte-associated protein 4), LAG-3 (lymphocyte activation gene 3), TIGIT (T-
cell immunoglobulin and ITIM domain), TIM-3 (T cell immunoglobulin and mucin 3),
CD160 and 2B4 (CD244).
PD-1, a member of the B7-CD28 superfamily, enforces an inhibitory program that blocks
further TCR-induced T-cell proliferation and cytokine production [18,19]. In HIV infection,
high levels of PD-1 are associated with T cell exhaustion [14–16,20] and incomplete immuno-
logical response to ART [21]. CTLA-4, a CD28 homolog, regulates the amplitude of T-cell acti-
vation by both outcompeting CD28 in binding CD80 and CD86, as well as actively delivering
inhibitory signals to T cells [13]. TIGIT, which also belongs to the B7/CD28 superfamily, acts as
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a co-inhibitory molecule by directly down regulating proliferation of human T cells [22], but
also by modulating cytokine secretion of DCs, decreasing IL-12 and enhancing IL-10 produc-
tions [23]. TIGIT has been recently associated with CD8+ T-cell dysfunction during HIV infec-
tion [24]. The expression of 2B4 (CD244), a member of the signalling lymphocyte activation
molecule (SLAM) is also modulated on T cells during HIV infection [17,25]. LAG-3, a member
of the immunoglobulin superfamily, is structurally highly homologous to the CD4 receptor and
share MHC-II as a ligand [26]. Its expression on T regulatory cells plays a role in the modulation
of T cell homeostasis and effector T cell responses [27,28]. TIM-3 is also an immunoglobulin
superfamily member and its expression is increased on HIV-specific CD8+ and CD4+ T cells
[29,30]. Finally, CD160, through its binding to its ligand Herpes Virus Entry Mediator
(HVEM), an atypical member of TNF-receptor superfamily, delivers a co-inhibitory signalling
to CD4+ T cells or CD8+ T cells dampening their activation in HIV-infected individuals [31,32].
To assess the relationship between the expression of these ICs and HIV persistence, we ana-
lysed the association between their levels of expression on CD4+ T cells and the size of the HIV
reservoir in individuals receiving ART for at least 3 years.
Materials and Methods
Study participants
Forty-eight HIV-infected participants receiving suppressive ART were recruited at the Univer-
sity of California San Francisco (UCSF) for this cross-sectional study. Participants were receiv-
ing ART for>3 years, had CD4+ T-cell count>350 cells/μl and HIV RNA<40 copies/mL as
measured by the Abbott real time HIV-1 PCR for at least 3 years. Whole blood (50mL) was col-
lected by regular blood draw. For cell sorting experiments, 27 HIV-infected individuals were
enrolled at UCSF and at VGTIFL and underwent leukapheresis.
Ethics statement
All subjects signed informed consent forms approved by the UCSF and Martin Memorial
Health Systems review boards (IRB #10–1320, Ref # 068192 and FWA #00004139,
respectively).
Immunophenotyping
PBMCs were isolated from peripheral blood and leukapheresis using previously described meth-
ods [6,33]. Cryopreserved PBMCs were thawed, washed and stained for phenotyping or cell
sorting. Two antibody panels were used to measure the expression of IC in subsets of memory
CD4+ T cells. The same antibody backbone was used in the two panels: CD3-Alexa700 (clone
UCHT1, BD#557943), CD4-QDot605 (clone S3.5, Invitrogen#Q10008), CD8-PB (clone
RPA-T8, BD#558207), CD14-V500 (clone M5E2, BD#561391), CD19-AmCyan (clone SJ25C1,
BD#339190), LIVE/DEAD Aqua marker (Invitrogen#L34957), CD45RA-APC-H7 (clone
HI100, BD#560674), CD27-BV650 (clone O323, Biolegend#302828) and CCR7-PE-Cy7 (clone
3D12, BD#557648). The following antibodies were added to this backbone: PD-1-AF647 (clone
EH12.1, BD#560838), CTLA-4-PE (clone BNI3, BD#555853), LAG-3-FITC (R&D#FAB2319F),
TIGIT-PerCP-eF710 (clone MBSA43, eBioscience#46-9500-41), TIM-3-PE (clone F38-2E2,
Biolegend#345006), CD160-AF488 (clone By55, eBioscience#53–1609), 2B4-PerCP-Cy5.5
(clone C1.7, Biolegend#329515). For expression of all ICs, gates were defined using fluorescence
minus one controls. CD4+ T-cell subsets were identified by CD27, CD45RA, and CCR7 expres-
sion on CD4+ T cells after exclusion of dump positive cells (LIVE/DEAD, CD14 and CD19). ICs
were measured in gated CD4+ T-cell subsets including naïve CD4+ T cells (CD3+CD8-CD4
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+CD45RA+CCR7+CD27+), central memory CD4+ T cells (CD3+CD8-CD4+CD45RA-CCR7
+CD27+), transitional memory CD4+ T cells (CD3+CD8-CD4+CD45RA-CCR7-CD27+), effec-
tor memory CD4+ T cells (CD3+CD8-CD4+CD45RA-CCR7-CD27-) and terminally differenti-
ated CD4+ T cells (CD3+CD8-CD4+CD45RA+CCR7-CD27-). Data was acquired on a BD LSR
II flow cytometer using the FACSDiva software (Becton Dickinson) and analysed using Flow Jo
version 9 (Treestar).
Cell sorting
Central, transitional and effector memory CD4+ T cells were sorted based on their expression
of PD-1, TIGIT or LAG-3. The antibodies used for sorting were similar than those used for
phenotyping with the exception of CD27-QDot655 (clone CLB-27/1, Invitrogen#Q10066). In a
second set of experiments, total memory CD4+ T cells (CD3+CD4+CD45RA-) were sorted
based on their expression of PD-1, TIGIT and LAG-3. Sorted cells were collected using an
ARIA FACS sorter (Becton Dickinson).
Isolation of total CD4+ T cells
Total CD4+ T cells were isolated from cryopreserved PBMCs using magnetic depletion as per
the manufacturer’s protocol (Stem Cell Technologies, Vancouver, Canada).
Quantification of integrated, total and 2-LTR circles HIV DNA, cell
associated unspliced HIV RNA and Tat/rev inducible multiply spliced
HIV RNA
Total CD4+ T cells or sorted CD4+ T cell subsets were used to measure the frequency of cells
harboring HIV DNA (total, integrated and 2-LTR circles) by real time nested PCR as previ-
ously described [34] (S1A Text).
The CA-US RNA was measured by real time nested PCR as previously described [35]. The
frequency of CD4+ T cells with inducible multiply spliced HIV RNA was determined using
Tat/rev inducible limiting dilution assay (TILDA) [36].
Statistical analysis
Data distributions were assessed through descriptive statistics and scatter plots. Negative bino-
mial regression models were run for each set of comparisons with the percentage of CD4+ T
cells expressing ICs being the predictor and the measure of HIV persistence the outcome. We
chose this approach for reasons described previously [12, 35], and for consistency with those
previous publications (S1B Text). The approach allowed us to fit models adjusting for the effects
of absolute current or nadir CD4+ T-cell, which were examined for all combinations of IC pre-
dictors and HIV persistence outcome measures. In addition, the negative binomial regression
models take into account that copies/input is measured with less precision when the number of
copies is lower and when the amount of input is lower. The methods also permit proper quanti-
tative use of instances where zero copies were present in the specimen assayed, without a need
for ad hoc modifications to permit taking logarithms. We did not evaluate the results of alterna-
tive analysis methods and did not choose the methods post-hoc based on the results that they
produced. Analyses were run in Stata version 13.1 (Stata Corp, College Station, TX).
For TILDA results analysis, we estimated the within-person fold difference in TILDA
between the 2 cell subsets analyzed (memory CD4+ T cells expressing any versus none of the
ICs) by fitting a maximum likelihood model to the raw data on numbers of positive and nega-
tive wells at each dilution (S1C Text).
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Results
PD-1, TIGIT and LAG-3 are associated with markers of HIV persistence
during ART
To determine the relationship between ICs and HIV persistence, 48 HIV-infected participants
on suppressive ART for a median time (IQR) of 8.5 years (5.0–12.4) and a median CD4+ T-cell
count (IQR) of 684 cells/μL (533–858) were recruited (Table 1). The expressions of 7 ICs on
CD4+ T cells (PD-1, CTLA-4, LAG-3, TIGIT, TIM-3, CD160 and 2B4) were measured by mul-
tiparametric flow cytometry (S1 Fig). The frequencies of CD4+ T cells expressing these ICs
were variable (median (IQR) of 16.7% (13.2–22.7), 12.2% (8.8–16.4), 12.0% (8.9–16.1), 9.5%
(3.5–18.5), 1.1% (0.8–2.5), 0.8% (0.6–1.5) and 0.7% (0.6–1.0) for TIGIT, PD-1, LAG-3, 2B4,
CD160, TIM-3 and CTLA-4 respectively) (Fig 1A).
The size of the HIV reservoir was determined by measuring the frequencies of CD4+ T cells
harboring integrated HIV DNA, total HIV DNA and 2-LTR circles as well as cell-associated
unspliced (CA-US) HIV RNA (Fig 1B and S1 Table). Total HIV DNA and cell-associated US
HIV RNA were detected in all samples tested, whereas integrated HIV DNA and 2-LTR circles
were detected in 98%, and 80% of the samples, respectively.
We evaluated the association between markers of HIV persistence and the frequencies of
CD4+ T cells expressing ICs using a negative binomial regression model that was adjusted for
current and nadir CD4+ T-cell counts when indicated (Table 2 and S2–S4 Tables). Using these
tailored analytical methods for HIV reservoir measurements, we identified 3 ICs for which the
expression on CD4+ T cells was statistically significantly associated with the frequency of CD4+
T cells harboring integrated HIV DNA, namely PD-1, TIGIT and LAG-3 (Fig 1C–1E and
Table 2). These correlations persisted after adjusting for nadir CD4+ T-cell counts but were no
longer significant after adjusting for current CD4+ T-cell count, a clinical parameter strongly
associated with the size of the reservoir during ART [6,37,38].
The frequency of PD-1 expressing CD4+ T cells was also associated with the frequency of
CD4+ T cells harboring total HIV DNA (S3 Table), but only marginally (1.23-fold effect,
p = 0.07) when the model was adjusted for current CD4+ T-cell count. CA-US HIV RNA and
2-LTR circles did not show statistically significant correlation with any IC expression levels,
with the exception of a negative association between the frequency of CD160+ CD4+ T cells
and 2-LTR circles that remained statistically significant after adjusting for current and nadir
CD4+ T-cell count (S3 and S4 Tables).
Table 1. Clinical demographics of the cohorts.
Characteristics Cohort 1 (N = 48) Cohort 2 (N = 31)
Gender, n (%)
Male 46 (96%) 29 (94%)
Female 1 (2%) 2 (6%)
Transgender 1 (2%) 0 (0%)
Age, yearsmedian (IQR) 57 (50–62) 50 (50–62)
Viral load, cop/mL <50 <50
Nadir CD4+ T-cell count, cells/μlmedian (IQR) 197 (110–285)a 42 (14–179)b
Current CD4+ T-cell count, cells/μlmedian (IQR) 684 (530–862) 526 (420–702)
Current CD8+ T-cell count, cells/μlmedian (IQR) 914 (639–1091) 830 (617–1135)
CD4/CD8 ratiomedian (IQR) 0.77 (0.57–1.17) 0.64 (0.40–0.91)
ART, yearsmedian (IQR) 8.5 (5.0–12.4) 8.8 (6.2–12.6)c
Data only available for (a) N = 45, (b) N = 27, (c) N = 24
doi:10.1371/journal.ppat.1005761.t001
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Fig 1. PD-1, TIGIT and LAG-3 are associated with virological markers of HIV persistence during ART. (A) Expression of 7 ICs on CD4+ T cells
in individuals receiving suppressive ART (n = 48). Data is represented as percentage of CD4+ T cells and horizontal bars indicate median values with
interquartile ranges. (B) Size of the HIV reservoir measured by integrated HIV DNA, total HIV DNA, 2-LTR circles represented as copies per million
CD4+ T cells and cell-associated US HIV RNA represented as copies per million copies of 18S. Horizontal bars indicate median values with
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Co-expression of PD-1, TIGIT and LAG-3 is a marker of HIV persistence
during ART
ICs are co-expressed on exhausted CD4+ and CD8+ T cells during untreated HIV infection
[39]. Using a Boolean gating strategy, we determined the frequency of CD4+ T cells co-express-
ing PD-1 and/or TIGIT and/or LAG-3 in our cohort of 48 HIV-infected participants receiving
suppressive ART (Fig 2A and 2B). The majority of CD4+ T cells did not express any of these
markers (median (IQR) of 65.8% (59.0–72.4)) (S6 Table). Less than 10% (8.5%) of CD4+ T
cells expressed more than one of these markers and 0.9% simultaneously expressed PD-1,
TIGIT and LAG-3. We further assessed if the frequency of these discrete CD4+ T-cell subsets
was associated with markers of HIV persistence. Using the negative binomial regression
model, we found that the frequency of CD4+ T cells not expressing PD-1, TIGIT and LAG-3
was strongly and negatively correlated to the frequency of CD4+ T cells harboring integrated
HIV DNA (p = 0.002, Table 3 and Fig 2C). Conversely, the frequency of CD4+ T cell co-
expressing PD-1, TIGIT and LAG-3 was strongly and positively associated with the frequency
of CD4+ T cells harboring integrated HIV DNA (p = 0.001, Table 3 and Fig 2F). Interestingly,
the frequencies of CD4+ T cells co-expressing TIGIT with either PD-1 or LAG-3 were also
positively associated with the frequency of CD4+ T cells harboring integrated HIV DNA
(p = 0.002 and p = 0.029 respectively, Table 3 and Fig 2D and 2E). Although several of these
associations were less or no longer statistically significant when the model was adjusted for the
current CD4+ T-cell count, the association between the size of the HIV reservoir and the fre-
quency of triple positive cells (PD-1+, LAG-3+ and TIGIT+) remained statistically significant
after adjustment (p = 0.038). Adjusting for duration of ART did not produce any substantial
interquartile ranges and open circles represent the limit of detection in the negative samples (based on cell input). (C), (D), (E) Associations between
the frequency of CD4+ T cells harboring integrated HIV DNA and the frequency of CD4+ T cells expressing PD-1, TIGIT and LAG-3, respectively. P
values were obtained from negative binomial regression analysis. Effect sizes for the associations are as follows: (C) A 2-fold increase in the
percentage of PD-1+ CD4+ T cell was associated with 1.43-fold increase in the frequency of CD4+ T cell harboring integrated HIV DNA, (D) a 2-fold
higher percentage of TIGIT+ CD4+ T cell was associated with 1.91-fold higher integrated HIV DNA and (E) a 2-fold higher percentage of LAG-3+
CD4+ T cell was associated with 1.62-fold higher integrated HIV DNA. Open circles represent the limit of detection in the negative samples (based on
cell input).
doi:10.1371/journal.ppat.1005761.g001
Table 2. Negative binomial regression models to assess the relationship between integrated HIV DNA and IC expression on CD4+ T cells.
Outcome Predictora Unadjusted Adjusted for Current CD4 Adjusted for Nadir CD4
Result (95%CI)c, d p-valuee Result (95%CI) p-value Result (95%CI) p-value
Integrated HIV DNA b PD1+ 1.43 (1.08 to 1.90) 0.012 1.17 (0.91 to 1.50) 0.220 1.39 (1.05 to 1.82) 0.020
CTLA-4+ 1.50 (0.90 to 2.51) 0.120 1.18 (0.73 to 1.91) 0.500 1.43 (0.88 to 2.35) 0.150
LAG-3+ 1.62 (1.07 to 2.45) 0.022 1.07 (0.69 to 1.65) 0.760 1.58 (1.07 to 2.35) 0.023
TIGIT+ 1.91 (1.11 to 3.28) 0.020 1.54 (0.91 to 2.60) 0.110 1.87 (1.10 to 3.16) 0.020
TIM-3+ 1.28 (0.83 to 1.97) 0.260 1.24 (0.85 to 1.80) 0.260 1.38 (0.89 to 2.14) 0.160
CD160+ 1.07 (0.82 to 1.39) 0.620 0.90 (0.69 to 1.17) 0.420 1.13 (0.86 to 1.48) 0.370
2B4+ 1.06 (0.83 to 1.36) 0.630 0.92 (0.71 to 1.18) 0.500 1.10 (0.87 to 1.39) 0.440
a Percentage CD4+ T cells that express Immune Checkpoint Molecules
b Integrated HIV DNA units (copies/million CD4+ T cells)
c 95% CI = 95% confidence interval
d Result interpretation: fold-change in the outcome (marker of HIV persistence) for each unit change of the predictor (Immune Checkpoint Molecules). All
predictors were log2 transformed, so results here are interpreted as the change in the outcome for each doubling of the predictor
e Statistically significant p values are <0.05 and are bold
doi:10.1371/journal.ppat.1005761.t002
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Fig 2. Co-expression of PD-1, TIGIT and LAG-3 is a marker of HIV persistence during ART. (A) Frequency of CD4+ T cells co-
expressing PD-1 and/or TIGIT and/or LAG-3 (PD-1/TIGIT/LAG-3 triple–(P-T-L-), PD-1 single + (P+), TIGIT single + (T+), LAG-3 single +
(L+), PD-1/TIGIT double + (P+T+), TIGIT/LAG-3 double + (T+L+), PD-1/LAG-3 double + (P+L+) and PD-1/TIGIT/LAG-3 triple + (P+T+L
+)) determined by Boolean gating in cohort 1 (n = 48). Horizontal bars indicate median values with interquartile ranges. (B) Venn
diagram showing the pattern of co-expression of PD-1, TIGIT and LAG-3. (C), (D), (E), (F) Associations between the frequency of CD4+
Immune Checkpoints and HIV Persistence during ART
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changes to the results from the unadjusted analysis (all fold-effects adjusted for ART duration
within 7% of those unadjusted). All together, these results indicate that the co-expression of
PD-1, TIGIT and LAG-3 identifies a unique subset of CD4+ T cells that strongly predicts the
frequency of cells harboring integrated HIV DNA during ART.
Expressions of PD-1, TIGIT and LAG-3 are associated with HIV-infected
cells in distinct memory CD4+ T-cell subsets during ART
HIV persists preferentially in memory CD4+ T-cell subsets [6–8]. To determine the role played
by ICs in each individual CD4+ T-cell memory subset, we first analyzed the expression of PD-
T cells harboring integrated HIV DNA and the frequency of CD4+ T cells expressing none of these markers (triple–), PD-1 and TIGIT
(double +), TIGIT and LAG-3 (double +) and PD-1 and TIGIT and LAG-3 (triple +), respectively. P values were obtained from negative
binomial regression analysis. Effect sizes for the associations are as follows: (C) 0.69-fold-change in integrated HIV DNA for 1 point
increase in percentage of PD-1/TIGIT/LAG-3 triple—CD4+ T cells, (D) 1.18-fold-change in integrated HIV DNA for 1 point increase in
percentage of PD-1/TIGIT double + CD4+ T cells, (E) 1.30-fold-change in integrated HIV DNA for 1 point increase in percentage of
TIGIT/LAG-3 double + CD4+ T cells and (F) 1.94-fold-change in integrated HIV DNA for 1 point increase in percentage of PD-1/TIGIT/
LAG-3 triple + CD4+ T cells. Open circles represent the limit of detection in the negative samples (based on cell input).
doi:10.1371/journal.ppat.1005761.g002
Table 3. Negative binomial regression models to assess the relationship between Integrated HIV DNA and the frequency of CD4+ T cells express-
ing PD-1 and/or TIGIT and/or LAG-3.
Outcome Predictora Unadjusted Adjusted for Current
CD4
Adjusted for Nadir CD4 Adjusted for ART
duration
Result
(95%CI) c, d
p-valuee Result (95%CI) p-value Result (95%CI) p-value Result
(95%CI)
p-value
Integrated HIV
DNAb
PD-1/TIGIT/LAG-3
triple –f
0.69 (0.54 to
0.87)
0.002 0.82 (0.65 to
1.03)
0.084 0.70 (0.56 to
0.86)
0.001 0.68 (0.54–
0.85)
0.001
PD-1 single +f 1.24 (0.90 to
1.70)
0.187 1.09 (0.80 to
1.48)
0.578 1.28 (0.94 to
1.75)
0.118 1.32 (0.93–
1.88)
0.12
TIGIT single + 1.06 (0.99 to
1.14)
0.106 1.05 (0.98 to
1.12)
0.210 1.06 (0.99 to
1.13)
0.111 1.06 (0.98–
1.14)
0.13
LAG-3 single + 1.00 (0.95 to
1.05)
0.963 0.97 (0.92 to
1.02)
0.176 1.00 (0.94 to
1.05)
0.848 1.00 (0.95–
1.05)
0.86
PD-1/TIGIT double + 1.18 (1.07 to
1.31)
0.002 1.13 (1.00 to
1.26)
0.042 1.17 (1.06 to
1.30)
0.003 1.19 (1.07–
1.32)
0.001
TIGIT/LAG-3 double + 1.30 (1.03 to
1.64)
0.029 1.16 (0.97 to
1.38)
0.100 1.27 (1.04 to
1.55)
0.018 1.29 (1.02–
1.65)
0.037
LAG-3/PD-1 double + 1.08 (0.96 to
1.23)
0.206 1.01 (0.88 to
1.16)
0.910 1.09 (0.96 to
1.25)
0.175 1.11 (0.96–
1.23)
0.15
PD-1/TIGIT/LAG-3
triple +
1.94 (1.33 to
2.83)
0.001 1.45 (1.02 to
2.05)
0.038 1.86 (1.26 to
2.72)
0.002 1.92 (1.31–
2.81)
0.001
a Percentage CD4+ T cells that express Immune Checkpoint Molecules
b Integrated HIV DNA units (copies/million CD4+ T cells)
c 95% CI = 95% confidence interval
d Result interpretation: fold-change in the outcome (marker of HIV persistence) for each one point increase in the percent of cells expressing the predictor
(PD-1 and/or TIGIT and/or LAG-3)
e Statistically significant p values are <0.05 and are bold
f These predictors vary more than others, so results are scaled to be per 10 point increase in percent of cells, rather than per one point increase
When the negative binomial regression model was used to assess the relationship between Total HIV DNA, 2-LTR circles, CA-US RNA and the frequency of
CD4+ T cells expressing PD-1 and/or TIGIT and/or LAG-3, no association show statistically significant, with the exception of the frequency of CD4+ T cells
harboring total HIV DNA and the frequency of PD-1 single + (p = 0.005, 1.10-fold-change in total HIV DNA for 1 point increase in percentage of PD-1 single
+ CD4+ T cells) and PD-1/TIGIT double + CD4+ T cells (p = 0.017, 1.40-fold-change in total HIV DNA for 1 point increase in percentage of PD-1/TIGIT
double + CD4+ T cells).
doi:10.1371/journal.ppat.1005761.t003
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1, TIGIT and LAG-3, the 3 ICs we identified to be associated with HIV persistence, on naïve
(TN), central memory (TCM), transitional memory (TTM), effector memory (TEM) and termi-
nally differentiated (TTD) cells in 48 HIV-infected participants (Cohort 1: clinical characteris-
tics in Table 1) (Fig 3A, 3B and 3C respectively). As expected, TN cells expressed low levels of
these ICs. The frequency of CD4+ T cells expressing PD-1 or LAG-3 increased with differentia-
tion, with TEM cells displaying the highest levels of expression of these markers. The highest
frequency of TIGIT+ cells was found within the TTM subset. These results demonstrated that
the subsets of memory cells that were previously shown to harbor persistent HIV during ART
express PD-1, TIGIT and LAG-3.
To determine whether PD-1, TIGIT and LAG-3 identify cells more likely to carry persistent
HIV in virally suppressed participants, individual memory CD4+ T-cell subsets were sorted based
on their expression of PD-1, TIGIT or LAG-3 in a subset of subjects who underwent leukapher-
esis (Cohort 2: clinical characteristics in Table 1) and the results were analyzed by negative bino-
mial regression model (S5 Table). The frequency of cells harboring integrated HIV DNAwas
moderately higher in PD-1 expressing TTM when compared to their PD-1 negative counterparts
(p = 0.053, fold-difference = 1.5) (Fig 3D). TEM cells expressing TIGIT were enriched for inte-
grated genomes when compared to their TIGIT- counterparts (p = 0.001, fold-difference = 2.7)
(Fig 3E). Finally, all the memory CD4+ T-cell subsets (TCM, TTM and TEM cells) expressing LAG-
3 were enriched for integrated HIV DNAwhen compared to their negative counterparts
(p<0.0001, fold-difference = 1.9, p = 0.003, fold-difference = 1.8 and p = 0.030, fold-difference = 2.5
respectively) (Fig 3F). All together these results indicate that PD-1, TIGIT and LAG-3 enrich for
infected cells in distinct memory CD4+ T-cell subsets in individuals on ART. We calculated the
contribution of cells expressing PD-1, TIGIT or LAG-3 to the total reservoir by taking into account
the frequency of these subsets within the CD4 compartment and their relative infection frequen-
cies. The mean contributions of CD4+ T cells expressing PD-1, TIGIT and LAG-3 were 29%, 34%
and 31%, respectively (S2 Fig). As a comparator, TCM, TTM and TEM cells contributed 43%, 27%
and 24% to the pool of infected cells in these same virally suppressed individuals. These data indi-
cate that a third of the reservoir is encompassed in cells expressing each individual marker.
Co-expression of PD-1, TIGIT and LAG-3 highly enriches in HIV-infected
memory CD4+ T cells during ART
We then determined if the combination of PD-1, TIGIT and LAG-3 would further enrich
memory CD4+ T cells for HIV-infected cells during ART. The average frequency of cells
expressing 0, 1, 2 or 3 of these markers in the memory CD4+ T compartment (CD45RA-) from
our cohort of 48 individuals (Table 1) indicated that an average of 33% of memory CD4+ T
cells expressed one of the 3 IC only, 12% expressed 2 and 2% expressed the 3 markers simulta-
neously. Large numbers of memory CD4+ T cells were sorted based on their expression of PD-
1, TIGIT and LAG-3 from 5 individuals. The combination of these 3 markers allowed us to
sort eight subsets of cells to high purity, namely PD-1/TIGIT/LAG-3 triple -, PD-1 single +,
TIGIT single +, LAG-3 single +, PD-1/TIGIT double +, TIGIT/LAG-3 double +, PD-1/LAG-3
double + and PD-1/TIGIT/LAG-3 triple + cells. The frequency of cells harboring integrated
HIV DNA was measured by qPCR in each sorted subset (S3 Fig) and the mean frequency for
each category was calculated relative to total CD4+ T cells (Fig 4B). Memory CD4+ T cells
showed a gradual enrichment in HIV-infected cells when expressing an increasing number of
ICs. Memory CD4+ T cells expressing simultaneously PD-1, TIGIT and LAG-3 were enriched
for HIV-infected cells up to 10 times more when compared to total CD4+ T cells, with a median
fold increase (IQR) of 8.15 (4.92–9.59). These results demonstrated that memory CD4+ T cells
expressing a combination of ICs were highly enriched for integrated HIV DNA during ART.
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Fig 3. PD-1, TIGIT and LAG-3 identify HIV-infected cells in distinct memory CD4+ T-cell subsets during ART. (A), (B), (C)
Frequencies of memory CD4+ T-cell subsets (naïve (TN), central memory (TCM), transitional memory (TTM), effector memory (TEM)
and terminally differentiated (TD)) expressing PD-1, TIGIT or LAG-3, respectively. Horizontal bars indicate median values with
interquartile ranges. (D), (E), (F) Frequencies of cells harboring integrated HIV DNA in TCM, TTM and TEM CD4
+ T-cell subsets
sorted based on their expression of PD-1 (n = 12), TIGIT (n = 9) or LAG-3 (n = 7), respectively. Results are expressed as the HIV
Immune Checkpoints and HIV Persistence during ART
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As the majority of HIV genomes, even when integrated, are defective [40], we assessed if
PD-1, TIGIT and LAG-3 identify cells in which HIV production can be induced. As the fre-
quency of triple positive cells was too low to perform this experiment, we sorted memory CD4+
T cells (CD45RA-) expressing any (i.e. at least one) versus none of PD-1, TIGIT or LAG-3
(mLPT+ and mLPT- respectively). We measured the frequency of cells in each population that
copy number in million cells of a given subset. P values were obtained from negative binomial regression analysis. Significant
differences (p<0.05) are designated by a p value in bold. Open circles represent the limit of detection in the negative samples
(based on cell input).
doi:10.1371/journal.ppat.1005761.g003
Fig 4. Co-expression of PD-1, TIGIT and LAG-3 identifies HIV-infected cells during ART. (A) Pie chart representing the frequencies of
memory CD4+ T cells co-expressing PD-1 and/or TIGIT and/or LAG-3 in cohort 1 (n = 48). Coloured bars on the right side designate categories of
ICs expressing cells: Triple -: PD-1/TIGIT/LAG-3 triple—in blue; single +: PD-1 single +, TIGIT single +, LAG-3 single + in green; double +: PD-1/
TIGIT double +, TIGIT/LAG-3 double +, PD-1/LAG-3 double + in orange and triple +: PD-1/TIGIT/LAG-3 triple + in red. (B) Frequency of memory
CD4+ T cells harboring integrated HIV DNA represented as a fold change over frequency in total CD4+ T cells. Mean values and standard
deviations from 5 independent donors are represented (n = 5). (C) Frequency of cells harboring inducible msRNAmeasured by TILDA in
memory CD4+ T cells expressing any (i.e. at least one) versus none of PD-1, TIGIT or LAG-3 (mLPT+ and mLPT- respectively). P value and fold-
difference were obtained from a maximum likelihood model.
doi:10.1371/journal.ppat.1005761.g004
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transcribe multiply spliced HIV RNAmolecules upon induction with PMA/ionomycin using
the Tat/rev induced limiting dilution assay (TILDA) [36]. Tat/rev transcripts were detectable
by TILDA in both cell subsets from all of the 8 individuals tested. The rate of inducible virus
per million cells was estimated in our maximum likelihood model to average 3.0-fold higher in
mLPT+ cells than in mLPT- cells from the same participant (95% CI 1.0 to 9.0, p = 0.049, S1C
Text) (Fig 4C). Taking into account the frequency of these cell subsets, the contribution of cells
expressing at least one of these markers to the total pool of memory CD4+ T cells infected with
inducible HIV genomes was calculated. This contribution ranged from 30 to 98% (median of
76%), indicating that the majority of inducible HIV genomes were found in memory CD4+ T
cells expressing at least one of these markers. These experiments provide evidence that memory
CD4+ T cells expressing PD-1, TIGIT and/or LAG-3 are enriched for HIV-infected CD4+ T
cells harboring inducible proviruses during ART.
Discussion
In this study, we identified PD-1, TIGIT and LAG-3 as novel markers of cells that are more fre-
quently infected in HIV-infected individuals receiving suppressive ART. Co-expression of the
3 ICs identified a unique subset of CD4+ T cells that was strongly associated with the size of the
HIV reservoir and that was highly enriched for integrated HIV DNA. Finally, our results pro-
vide evidence that memory CD4+ T cells expressing at least one of these markers are the major
contributors to the pool of inducible HIV genomes during ART.
The frequencies of CD4+ T cells expressing PD-1, CTLA-4, LAG-3 and TIM-3 were similar
to those reported by other groups [41–44], indicating that the cohort of participants used for
this study is likely to be representative of the HIV population receiving suppressive ART. In
addition, the association between PD-1 and TIGIT expression on CD4+ T cells and the fre-
quency of CD4+ T cells carrying HIV proviruses was in agreement with previously reported
findings [6,24,41].
We found positive associations between the expression of PD-1, LAG-3 and TIGIT in CD4+
T cells and the frequency of cells harboring integrated HIV DNA. Of note, these three markers
showed the strongest inverse associations with CD4+ T cell counts among the 7 markers we
examined, suggesting a link between T cell homeostasis and HIV persistence (S4A, S4B and
S4C Fig). The associations between individual IC expression and HIV persistence marker were
substantially smaller and no longer statistically significant after adjusting for current CD4+ T-
cell count. These findings from the negative binomial regression models suggest that the cur-
rent CD4+ T-cell count is an important predictor of the size of the HIV reservoir when mea-
sured as the frequency of cells harboring proviral genomes [6,37]. Importantly, and in contrast
to cells expressing a single marker, the frequency of cells co-expressing simultaneously PD-1,
TIGIT and LAG-3 was strongly associated with the size of the reservoir and remained after
adjusting for nadir and current CD4+ T-cell counts. This result reinforces the possibility of a
direct—and maybe synergistic—role for these molecules in HIV persistence during ART. In
addition, the frequency of CD4+ T cells co-expressing simultaneously PD-1, TIGIT and LAG-3
positively correlated with the frequency of CD4+ T cells expressing HLADR/CD38 (p = 0.003,
r = 0.42) and Ki67 (p = 0.022, r = 0.33) (S1D and S1E Text and S4D and S4E Fig). These associ-
ations suggest that the persistence of the small pool of cells expressing the 3 markers is associ-
ated with T cell activation and proliferation.
Interestingly, we observed a strong negative association between CD160 expression and
2-LTR circles. Notably, this correlation remained after adjusting for current and nadir CD4+ T
cell counts. A possible explanation for these findings is that CD160+ cells may be preferential
targets for infection and depletion during ART, which would explain the strong negative
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association between the frequency of CD160+ CD4+ T cells and a putative marker of persistent
viral replication.
By sorting TCM, TTM and TEM cells expressing PD-1, TIGIT and LAG-3, we observed that
cells expressing these markers were enriched for HIV-infected cells in different memory CD4+
T-cells subsets during ART. While LAG-3 enriched for integrated HIV DNA in all memory
subsets (TCM, TTM, and TEM), PD-1 and TIGIT enriched for HIV genomes exclusively in TTM
and TEM cells, respectively. These observations suggest that ICs may exert different pro-latency
effects in subsets endowed with distinct proliferative and activation status. One may hypothe-
size that different ICs provide infected cells with different selective advantage to persist by
counteracting distinct stimuli specific to an individual memory cell subset. Further investiga-
tions will be needed to characterize the mechanisms by which these ICs may specifically con-
tribute to HIV persistence within these distinct subsets.
Overall, the majority of inducible HIV genomes were found in memory CD4+ T cells
expressing at least one of these markers (median of 76%). Although triple negative cells also
contain inducible HIV genomes, our data provide evidence that there is an enrichment for
inducible viral genomes in CD4+ T cells expressing these markers.
Importantly, we found a gradual enrichment in integrated HIV DNA in cells that express
multiple ICs simultaneously. This observation mirrors the synergistic mechanisms of action of
these receptors to dampen T cell functions. Indeed, LAG-3 and PD-1 are commonly co-
expressed on exhausted or dysfunctional T cells in models of chronic infections [45], autoim-
mune diseases [46], and cancers [47,48]. Potential synergistic functions were highlighted in
murine models of autoimmune diseases [49]. Anti-LAG-3 blocking mAb has recently entered
clinical testing in cancer in monotherapy or in combination therapy with anti-PD-1
(NCT01968109). Additionally, TIGIT is co-expressed with PD-1 on activated CD8+ tumor-
infiltrating lymphocytes from patients with melanoma [50]. Blockages of TIGIT and PD-1
synergize to improve T cell proliferation, cytokines production and degranulation in vivo in
melanoma treatment and in vitro in HIV infection [24,50]. All together, these studies indicate
that ICs can synergize to repress T cell functions and suggest that these synergies may also play
a role in HIV persistence during ART.
The expression of PD-1, LAG-3 and TIM-3 on CD4+ and CD8+ T cells prior to ART was
recently identified as a strong predictor of time to viral rebound after treatment interruption in
the SPARTAC study [43]. It is possible that CD4+ T cells expressing these markers before ART
represent a preferential niche for the establishment of a stable reservoir for HIV and that
latently infected cells expressing these markers preferentially persist during ART, as suggested
by our observations. In our study, we identified a discrete subset of CD4+ T cells co-expressing
PD-1, TIGIT and LAG-3 as an important predictor of the frequency of cells harboring inte-
grated HIV DNA during ART. Of note, the expression of TIGIT before ART initiation was not
measured in the SPARTAC study and further studies will be needed to determine if this IC
could also represent a pre-ART predictor of viral rebound.
Our data provide a rationale for the use of immune checkpoint blockers (ICBs) to target
latently infected cells during ART. Targeting ICs by ICBs, a novel class of molecules in develop-
ment in oncology, may have a double benefit in the context of HIV remission by both targeting
latently infected cells and restoring HIV-specific T cell immunity. By enhancing T cell activa-
tion and increasing viral transcription, ICBs may facilitate HIV reactivation in latently infected
cells when used alone or in combination with latency reversing agents. The anti-CTLA-4 anti-
body iplimumab was recently shown to significantly increase CA-US HIV RNA in an HIV-
infected individual on ART, consistent with latency reversal [51]. An alternative mechanism of
action of some ICBs would be to directly deplete cells expressing these markers, as observed
with the anti-CTLA-4 ipilumimab, which induces direct elimination of CTLA-4+ regulatory T
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cells in tumor tissue in patients with melanoma [52]. Our results suggest that the administra-
tion of antibodies with effector functions targeting PD-1, LAG-3 and TIGIT may significantly
reduce the size of the latent HIV reservoir during ART by targeting cells in which HIV persists.
Several limitations are associated with our study. We have not adjusted p-values for multiple
comparisons, because such adjustment would neglect the biological relationships among our
positive results and would require that each analysis detract from the others, rather than rein-
forcing one another when there is biological coherence [53] (S1F Text). Nevertheless, our evi-
dence may be weaker than if it had arisen from a narrower set of analyses, and, in any case,
additional studies will be needed to confirm the hypotheses supported by our results. Most of
our analyses were performed using integrated HIV DNA as a marker of HIV persistence. We
chose this readout as it was applicable to small subsets of CD4+ T cells on which measures of
replication competent HIV cannot be performed. The majority of viral genomes persisting dur-
ing ART are known to be defective [40,54], and although our experiments indicate that cells
that express ICs can produce multiply spliced RNA upon activation (TILDA), they do not
demonstrate that replication competent virus persists in these cells. In addition, our results are
limited to circulating T cells. It is possible and indeed likely that the biology of ICs expression
and HIV persistence will differ in tissues, particularly in secondary lymphoid tissues where
many of the ligands for these receptors are likely to be expressed.
A better understanding of the nature of the cells that encompass the latent HIV reservoir is
a prerequisite to the development of novel curative strategies. Despite similarities in their
mechanisms of action, PD-1, TIGIT and LAG-3 are likely to be non-redundant in their func-
tions. Blocking these pathways simultaneously may show synergies in latency reversal, as sug-
gested by their synergistic activities in the restoration of T cell immunity.
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